MGL-3196 Market Size, Forecast, and Market Insight - 2032

"MGL-3196 Market Size, Forecast, and Market Insight - 2032" report provides comprehensive insights about MGL-3196 for Non-alcoholic Steatohepatitis (NASH) in the seven major markets. A detailed picture of the MGL-3196 for NASH in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the MGL-3196 for NASH. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the MGL-3196 market forecast analysis for NASH in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in NASH.

Drug Summary:

Resmetirom (formerly MGL-3196) is a thyroid hormone receptor B-agonist. Thyroid hormone receptors can be classified as a-receptors and B-receptors, and activating the a-receptor results in all of the symptoms associated with more thyroid gland activity. On the other hand, thyroid hormone receptor B-agonism affects metabolic processes by lowering serum lipids such as LDL cholesterol, serum triglycerides, and other metabolic factors. There is a possibility that these changes could lower liver fat and reduce the toxicity of fat in the liver of patients with non-alcoholic fatty liver disease (NAFLD). Thus, by engaging the thyroid B-receptor, the patient does not experience symptoms of thyrotoxicosis or the toxic effect of the thyroid hormone, which is mediated through the a-receptor. The primary mechanism of action suggests potentially improving the patient's lipid profile and hepatic fat.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the MGL-3196 description, mechanism of action, dosage and administration, research and development activities in Non-alcoholic Steatohepatitis (NASH).
• Elaborated details on MGL-3196 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the MGL-3196 research and development activities in NASH across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around MGL-3196.
• The report contains forecasted sales of MGL-3196 for NASH till 2032.
• Comprehensive coverage of the late-stage emerging therapies for NASH.
• The report also features the SWOT analysis with analyst views for MGL-3196 in NASH.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

MGL-3196 Analytical Perspective by DelveInsight

• In-depth MGL-3196 Market Assessment

This report provides a detailed market assessment of MGL-3196 for Non-alcoholic Steatohepatitis (NASH) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• MGL-3196 Clinical Assessment

The report provides the clinical trials information of MGL-3196 for Non-alcoholic Steatohepatitis (NASH) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Non-alcoholic Steatohepatitis (NASH) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence MGL-3196 dominance.
• Other emerging products for NASH are expected to give tough market competition to MGL-3196 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of MGL-3196 in NASH.
• Our in-depth analysis of the forecasted sales data of MGL-3196 from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the MGL-3196 in NASH.

Key Questions:

• What is the product type, route of administration and mechanism of action of MGL-3196?
• What is the clinical trial status of the study related to MGL-3196 in Non-alcoholic Steatohepatitis (NASH) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the MGL-3196 development?
• What are the key designations that have been granted to MGL-3196 for NASH?
• What is the forecasted market scenario of MGL-3196 for NASH?
• What are the forecasted sales of MGL-3196 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to MGL-3196 for NASH?
• Which are the late-stage emerging therapies under development for the treatment of NASH?